GENinCode
GENI · AIM · Health Care · mcap £4.9m · 0.6p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 30 Sep 26 | Holding | Holding(s) in Company | |
| 29 Sep 26 | Results | Half-year Results
GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease (“CVD”) and risk of ovarian cancer announces its unaudited interim results for the six months ended 30 June 2 |
−20.0% |
| 22 Sep 26 | Routine | Notice of Results | |
| 28 Aug 26 | Results | CARDIO inCode-Score milestone clinical results
CARDIO inCode-Score® milestone clinical results for prevention of coronary artery disease |
+10.5% |
| 01 Jul 26 | Routine | Result of AGM | |
| 11 Jun 26 | Holding | Holding(s) in Company | |
| 10 Jun 26 | Holding | Holding(s) in Company | |
| 08 Jun 26 | Results | Final Results
Well positioned for accelerated commercial scale up with revenue growth and expanding US adoption |
−13.0% |
| 04 Jun 26 | Holding | Holding(s) in Company | |
| 03 Jun 26 | Holding | Holding(s) in Company | |
| 22 May 26 | Routine | Notice of Results | |
| 08 May 26 | Holding | Holding(s) in Company | |
| 07 May 26 | Director dealing | Grant of Share Options & PDMR Dealings
Grant of Share Options, Surrender of Existing Options & PDMR Dealings |
−14.3% |
| 15 Apr 26 | Holding | Holding(s) in Company | |
| 14 Apr 26 | Holding | Holding(s) in Company | |
| 26 Feb 26 | Holding | Holding(s) in Company | |
| 24 Feb 26 | Holding | Holding(s) in Company | |
| 12 Feb 26 | Holding | Holding(s) in Company | |
| 12 Feb 26 | Holding | Holding(s) in Company | |
| 12 Feb 26 | Holding | Holding(s) in Company | |
| 09 Feb 26 | Director dealing | Result of GM, Director Shareholdings and TVR
Result of General Meeting, Director Shareholdings and Total Voting Rights |
+0.0% |
| 06 Feb 26 | Fundraise | Additional Subscription
GENinCode (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer, is pleased to announce that further to the Fundraising initially announced on 21 January 2026 |
+0.0% |
| 26 Jan 26 | Fundraise | Result of Retail Offer
GENinCode (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer, is pleased to announce that the WRAP Retail Offer launched on 21 January 2026 has now closed, |
−4.5% |
| 22 Jan 26 | Fundraise | Result of Placing and Subscription
Further to the announcement made yesterday regarding a proposed placing, subscription and retail offer (the "Launch Announcement"), GENinCode plc (AIM: GENI) is pleased to announce that, it has conditionally raised gross |
−37.8% |
| 21 Jan 26 | Fundraise | Retail Offer
GENinCode Plc (AIM: GENI), the genetics company focused on the prevention of cardiovascular disease ("CVD") and the early detection of ovarian cancer, is pleased to announce a retail offer via the Winterflood Retail Acce |
−2.6% |
| 21 Jan 26 | Fundraise | Placing and Subscription
THIS ANNOUNCEMENT SHOULD BE READ IN ITS ENTIRETY. |
−2.6% |
| 17 Dec 25 | Collaboration with Sohin Genetics
for the genetic risk prediction and prevention of coronary heart disease |
−1.8% | |
| 08 Dec 25 | Holding | Holding(s) in Company | |
| 04 Dec 25 | Collaboration with Thermo Fisher
Commercialisation agreement to sell, distribute and manufacture CARDIO inCode-Score® |
+30.0% | |
| 03 Dec 25 | Approval of CARDIO inCode-score in New York state
New York State clinical test approval of CARDIO inCode-score® |
+39.5% | |
| 27 Oct 25 | Publication of Landmark Study in JACC: Advances
Validation of CARDIO inCode-Score® for improved coronary heart disease risk prediction |
+1.6% | |
| 13 Oct 25 | Holding | Holding(s) in Company |
Company filings. Not investment advice.